Invitae sets IPO terms; Motif Bio out to raise £16M; OptiKira launches;

@FierceBiotech: Acorda cautiously steps forward with a drug to spur remyelination in MS. Story | Follow @FierceBiotech

@JohnCFierce: Biotech guru Gregory Verdine lands $18M round for new WaVe drug developer. Article | Follow @JohnCFierce

@DamianFierce:  Cannot help but read Theravance's ticker, $TBPH, as "to be perfectly honest." | Follow @DamianFierce

> San Francisco-based Invitae has set terms for its $75 million IPO, looking to sell 5.4 million shares at $13 to $15 each. Story

> Motif Bio is looking to raise up to £16 million on London's Alternative Investment Market for its antibiotics R&D work. Story

> OptiKira launched today with plans to develop develop small molecule therapeutics that prevent cell death in pathologies caused by misfolded or unfolded proteins. The biotech has IP out of UCSF and University of Washington. Release

Medical Device News

@FierceMedDev: ICYMI: Stomach-draining obesity startup gets $12M in debt to support PMA in mid-2015. Report | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Zimmer CEO says Biomet merger to close soon and result in $270M of synergies. Article | Follow @VarunSaxena2

@EmilyWFierce: Medical experts question procedures for peripheral artery disease amid Medicare payment surges. Article | Follow @EmilyWFierce

> With Covidien deal in the bag, Omar Ishrak urges Medtronic employees to stay focused on the company mission. More

> Medtronic touts study results in support of its defibrillator tech. Article

Pharma News

@FiercePharma: Abaxis scores strong earnings on record veterinary sales. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: FTC approves Sun Pharma Ranbaxy merger. Ranbaxy to sell its minocycline business to Torrent. More | Follow @EricPFierce

> Mylan's women's health biz leaps to fore in emerging markets with $750M Famy deal. Story

> J&J lawyers aim to discredit ex-FDA chief in Risperdal breast-development case. Report

> Amid new drug negotiations, China puts price-management vet in charge of CFDA. Article

Biotech IT News

> Biogen taps Google's data analytics skills for MS research. News

> Duke moves into new digs to support Google Baseline collaboration. Item

> 21st Century Cures Act lays out vision for sharing health data with R&D. Story

> Obama puts giant database at the heart of precision medicine plan. Report

> Alexion enlists BioXcel for data dive in search of next Soliris. Article

CRO News

> Post-merger Simbec-Orion inks two Phase III deals. Article

> Drugmakers look to India for drug safety monitoring. Item

> Belgian CRO genae buys an eClinical outfit. News

> Icon adding 200 jobs with a new Irish R&D outpost. Story

> Parexel dials down its 2015 expectations and takes the long view. Report

Animal Health News

> European regulators chart record year for new animal health products. Item

> Abaxis scores strong earnings on record veterinary sales. Story

> Report: Activist investor Ackman pushing for Zoetis board positions. More

> Virus linked to hemorrhagic fever found in Florida ticks. Report

> Diagnostics makers face regulatory, cost hurdles in animal health market. Article

Suggested Articles

The action will see Kiadis switch its attention to earlier-stage natural killer cell therapies against solid tumors and hematological cancers.

The Weill Family Foundation is stumping up $106 million to create a so-called “Neurohub.”

The takeover centers on TRPML1 agonists designed to treat neurodegenerative disorders by clearing toxic proteins from the brain.